Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now full pipeline small index

Idiopathic Short Stature: full-pipeline trial registry

3 of 5 indexed Idiopathic Short Stature trials are currently recruiting.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 3 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Idiopathic Short Stature: 5 US clinical trials tracked, 3 recruiting.

Idiopathic Short Stature is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is BioMarin Pharmaceutical, running 2 of these trials.

Enrollment posture brief

Registry condition idiopathic-short-stature

OPEN 3 | RECR 60% | LATE 2 | EARLY 2 | RANK #3391 | SPON 2

Nearest open-share peer: Acute Kidney Injury (AKI) (60% recruiting · 5 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Idiopathic Short Stature (th…60%
Open-enrollment share among volume-matched conditions near Idiopathic Short Stature

Idiopathic Short Stature lists 3 open slots (60% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Idiopathic Short Stature on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Idiopathic Short Stature is recruiting above its size-band peers.

    3 of 5 indexed trials (60%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Idiopathic Short Stature research.

    BioMarin Pharmaceutical accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.

  3. Typical Idiopathic Short Stature enrolment sits around 136 participants.

    Median target enrolment is 136 among the 5 trials that report a genuine target (sentinel values excluded). 1 of those (20%) plan for fewer than 100 participants.

  4. Idiopathic Short Stature research is mostly interventional.

    4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 21Phase 32

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1
Phase 3 2

Top Sponsors

Named interventions

Most-linked intervention names on Idiopathic Short Stature records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

somatropin Drug
1 trials
New Genotropin Pen Device
1 trials
Somatropin Pen Injector Combination
1 trials
Lonapegsomatropin [SKYTROFA®] Combination
1 trials
Human Growth Hormone Drug
1 trials
Vosoritide Injection Drug
1 trials
Placebo Drug
1 trials

US sites by state

Facility locations filed on Idiopathic Short Stature trials. A trial with sites in several states counts in each.

Idaho 3 trials
Florida 3 trials
California 3 trials
Louisiana 2 trials
Kentucky 2 trials
Indiana 2 trials
Georgia 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Idiopathic Short Stature page

5 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Idiopathic Short Stature condition card totals 5 registered trials; most-linked intervention somatropin; top US site state Idaho. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.